YANG, X., MENG, F., & ZHONG, D. (2023). Initial Treatment of Aumolertinib in Combination with Bevacizumab for Advanced NSCLC with Primary EGFR T790M Mutation: A Report of Three Cases and Literature Review. Chinese Anti-Cancer Association; Chinese Antituberculosis Association.
Chicago Style (17th ed.) CitationYANG, Xue, Fanlu MENG, and Diansheng ZHONG. Initial Treatment of Aumolertinib in Combination with Bevacizumab for Advanced NSCLC with Primary EGFR T790M Mutation: A Report of Three Cases and Literature Review. Chinese Anti-Cancer Association; Chinese Antituberculosis Association, 2023.
MLA (9th ed.) CitationYANG, Xue, et al. Initial Treatment of Aumolertinib in Combination with Bevacizumab for Advanced NSCLC with Primary EGFR T790M Mutation: A Report of Three Cases and Literature Review. Chinese Anti-Cancer Association; Chinese Antituberculosis Association, 2023.